Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. TSLA
2. SPY
3. META
4. INTC
5. HOOD
6. STZ
7. FUTU
8. AMZN
9. MSFT
10. SPCX

Go back to Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
(NASDAQ: CMND) Delayed: 2.36 +0.06 (2.61%)
Previous Close $2.30    52 Week High $ 
Open $2.28    52 Week Low $ 
Day High $2.42    P/E N/A 
Day Low $2.28    EPS $ 
Volume 66,623